NCT06183047

Brief Summary

The results of the study suggest that an early change in CgA levels might serve as a prognostic factor in NET patients treated with PRRT.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
38

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Oct 2016

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2016

Completed
7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2023

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 13, 2023

Completed
14 days until next milestone

First Posted

Study publicly available on registry

December 27, 2023

Completed
Last Updated

December 27, 2023

Status Verified

December 1, 2023

Enrollment Period

7 years

First QC Date

December 13, 2023

Last Update Submit

December 13, 2023

Conditions

Early Release of Chromogranin A (CgA)

Outcome Measures

Primary Outcomes (1)

  • The CgA level change

    We aimed to assess the predictive value of early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).

    2016-2023

Study Arms (1)

patients with neuroendocrine tumours

We aimed to assess the predictive value of early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).

Diagnostic Test: early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).

Interventions

early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).DIAGNOSTIC_TEST

early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).

patients with neuroendocrine tumours

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).

You may qualify if:

  • confirmed NET
  • peptide receptor radionuclide therapy (PRRT)

You may not qualify if:

  • lack of patient consent to a clinical trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Genes, fms

Intervention Hierarchy (Ancestors)

Proto-OncogenesOncogenesGenes, NeoplasmGenesGenome ComponentsGenomeGenetic StructuresGenetic Phenomena

Study Officials

  • Andrzej Mazurek, MD

    Military Institute of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Target Duration
80 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 13, 2023

First Posted

December 27, 2023

Study Start

October 1, 2016

Primary Completion

September 30, 2023

Study Completion

September 30, 2023

Last Updated

December 27, 2023

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will not share